Join to view full profile
100 Cummings CenterSuite 241-DBeverly, MA 01915
Dr. Bolger is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Graeme Bolger is the founder and CEO of BZI Pharma LLC , based in the Boston area. He has held positions as a senior medical director at Oncology Analytics, Inc., and as an associate and assistant professor at the University of Alabama and University of Utah, respectively. He has published extensively on topics related to signaling pathways and phosphodiesterases. His work has been recognized by multiple CMS Meaningful Use Stage 1 Certifications and listings as one of America's Top Doctors.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
Johns Hopkins UniversityResidency, Internal Medicine, 1981 - 1984
McGill University Faculty of MedicineClass of 1981
Certifications & Licensure
AL State Medical License 2000 - 2024
UT State Medical License 1994 - 2002
WA State Medical License 1984 - 1995
MD State Medical License 1984 - 1994
NY State Medical License 1991 - 1994
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MyHealth@UABMedicine, UAB Health System, 2012, 2014
- CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2012, 2014
- CMS Meaningful Use Stage 1 Certification Powerchart and Cerner Healthe, Cerner Corporation, 2012, 2014
Publications & Presentations
PubMed
- 27 citationsCyclic nucleotide phosphodiesterases as drug targets.Michy P Kelly, Viacheslav O Nikolaev, Leila Gobejishvili, Claire Lugnier, Christian Hesslinger
Pharmacological Reviews. 2025-05-01 - 25 citationsThe cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway.Graeme B Bolger
Frontiers in Endocrinology. 2022-01-01 - 27 citationsThe PDE-Opathies: Diverse Phenotypes Produced by a Functionally Related Multigene Family.Graeme B. Bolger
Trends in Genetics. 2021-04-05
Journal Articles
- The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform.Yarwood, S.J., Steele, M.R., Scotland, G., Houslay, M.D., Bolger, G.B., J. Biol. Chem, 1999
- Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D geneBolger, Biochem J, 1997
- Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3Huston, E, Biochem J, 1997
Press Mentions
New Clinical Decision Support Tool for Molecular and Genetic Testing LaunchedSeptember 2nd, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: